R Squared’s Immunome IMNM Stock Holding History

R Squared’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,410	Closed	-$15K	–	858
2024 Q4	$15K	Buy	+1,410	New	+$17K	0.01%	1012

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

R Squared's IMNM Position: Q1 2025 in Review

R Squared sold out of Immunome (IMNM) in Q1 2025, closing a stake of 1,410 shares — an estimated $15K sold.

R Squared first reported a position in IMNM in Q4 2024 and held it in 1 quarter. The position peaked at $15K in Q4 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q1 2025.

R Squared reported no remaining Immunome position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,410 Immunome shares in Q1 2025, an estimated $15K.
R Squared first reported a position in Immunome in Q4 2024 and held it in 1 quarter.
R Squared's Immunome position peaked at $15K in Q4 2024.
142 funds tracked by Wall St. Rank held Immunome as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.